Physician
Global Cancer Research Institute, INC.
Global Cancer Research Institute, INC. was paid $76K by Medicaid between Jan 2018 and Nov 2024, across 25 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 58% of everything it billed.
33Billing provider infoGLOBAL CANCER RESEARCH INSTITUTE, INC.
LOS GATOS, CA 95032
LOS GATOS, CA 95032
33aNPI1134489164assigned 05/24/2012
33bProvider typeHematology & Oncology Physician
28Total paid$76K
24GClaims7,904
24DCodes billed25
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in California
Rank by total paid#61 of 180
Median peer was paid$26K
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,472 | $17K | |
| 2019 | 1,297 | $16K | |
| 2020 | 1,273 | $11K | |
| 2021 | 1,155 | $9K | |
| 2022 | 1,150 | $10K | |
| 2023 | 799 | $9K | |
| 2024incomplete | 758 | $4K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 58% | 2,827 | 2,404 | $44K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.7% | 821 | 548 | $5K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 6.7% | 250 | 209 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 6.2% | 313 | 142 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.1% | 875 | 627 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 3.9% | 797 | 367 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.8% | 167 | 98 | $3K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 3.2% | 254 | 128 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 3.0% | 546 | 287 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.1% | 183 | 86 | $871.51 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 103 | 53 | $683.34 |
| 96368 | <1% | 121 | 64 | $565.21 |
13 more codes
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 126 | $389.40 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 35 | $214.42 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 87 | $190.50 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 86 | $94.20 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 18 | $51.22 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 107 | $47.74 |
| 99070 | <1% | 31 | $25.50 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 38 | $2.45 |
| A4208 | Syringe with needle, sterile 3 cc, each | <1% | 21 | $0.30 |
| A4215 | Needle, sterile, any size, each | <1% | 21 | $0.28 |
| A6216 | Gauze, non-impregnated, non-sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 29 | $0.00 |
| 36140 | 0% | 26 | $0.00 | |
| A6260 | Wound cleansers, any type, any size | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUI, LYNNE (PRESIDENT/CEO)